What will happen at the end of the main part of the study?
The results will be published in health or scientific journals, on websites (including ClinicalTrials.gov & www.clinicaltrialsregister.eu) and will be discussed at major conferences. Others will learn from the results, which we hope will show that more lives can be saved by using empagliflozin. No individual participant will be identified in any report or publication.
We will try our best to inform participants and their GPs of the study results, and any related publicity. We will use study newsletters and videos on the study’s website to inform people about what the study shows.
Participants' contribution to the study could be even more valuable if we have their permission to get information about their health after the very last study appointment. This way we can learn about any longer-term health effects of the study pills. This might include a questionnaire or phone call once a year. Also, the study scientists can continue to get information about participants' health, such as details from local doctors, NHS Digital (or other central NHS registry) and the UK Renal Registry.